Recruiting Liver Cancer Studies in New York
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremel...
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced soli...
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
This study will compare the safety and effects of HAI floxuridine and dexamethasone combined with the standard chemotherapy drugs gemcitabine and oxaliplatin (GemOx) with those of GemOx alone in peopl...
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
The objective of this study is to investigate the safety, tolerability and preliminary activity of ivosidenib in combination with durvalumab and gemcitabine/cisplatin as first-line therapy in particip...
A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma
This Phase 1/ 2a study is a multicenter study to evaluate the safety, tolerability and efficacy of SCG101 in subjects with hepatitis B virus-related hepatocellular carcinoma...
About Liver Cancer Clinical Trials in New York
Liver cancer most commonly presents as hepatocellular carcinoma (HCC) and is often associated with chronic liver disease or hepatitis. It is one of the fastest-growing causes of cancer death. Treatment options include surgery, liver transplant, ablation, and systemic therapies.
There are currently 5 liver cancer clinical trials recruiting participants in New York, NEW%20YORK. These studies are seeking a combined 1,742 participants. Research is being sponsored by AstraZeneca, Memorial Sloan Kettering Cancer Center, Institut de Recherches Internationales Servier and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Liver Cancer Clinical Trials in New York — FAQ
Are there liver cancer clinical trials in New York?
Yes, there are 5 liver cancer clinical trials currently recruiting in New York, NEW%20YORK. Browse the studies on this page to find one that fits.
How do I join a clinical trial in New York?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you about next steps.
Are clinical trials in New York free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New York studies also compensate for your time and travel.
What liver cancer treatments are being tested?
The 5 active trials in New York are testing new therapies including novel drugs, biologics, and treatment approaches for liver cancer.
Data updated March 2, 2026 from ClinicalTrials.gov